|
Report Date : |
01.04.2014 |
IDENTIFICATION DETAILS
|
Name : |
YES PHARMA LTD. |
|
|
|
|
Registered Office : |
11 Hamelacha Street Har Tuv A Industrial Park Nocham Enterprises Har-Tuv 9980101 |
|
|
|
|
Country : |
Israel |
|
|
|
|
Date of Incorporation : |
17.01.2005 |
|
|
|
|
Legal Form : |
Private Limited Company |
|
|
|
|
Line of Business : |
· Agencies in the field of raw materials for the pharmaceutical (pharma Intermediates, Active Pharmaceuticals Ingredient's (APIs), formulations to biopharmaceuticals). · Also international traders in raw materials for the pharmaceutical field. |
|
|
|
|
No. of Employees : |
14 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
Payment Behaviour : |
No complaints |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – September 30, 2013
|
Country Name |
Previous Rating (30.06.2013) |
Current Rating (30.09.2013) |
|
Israel |
A2 |
A2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
ISRAEL - ECONOMIC OVERVIEW
Israel has a technologically
advanced market economy. Its major imports include crude oil, grains, raw
materials, and military equipment. Cut diamonds, high-technology equipment, and
pharmaceuticals are among the leading exports. Israel usually posts sizable
trade deficits, which are covered by tourism and other service exports, as well
as significant foreign investment inflows. The global financial crisis of
2008-09 spurred a brief recession in Israel, but the country entered the crisis
with solid fundamentals - following years of prudent fiscal policy and a
resilient banking sector. The economy has recovered better than most advanced,
comparably sized economies. In 2010, Israel formally acceded to the OECD.
Israel's economy also has weathered the Arab Spring because strong trade ties
outside the Middle East have insulated the economy from spillover effects.
Natural gasfields discovered off Israel's coast since 2011 have brightened
Israel's energy security outlook. The Leviathan field was one of the world's
largest offshore natural gas finds this past decade, and production from the
Tamar field started meeting all of Israel's natural gas demand in 2013. In
mid-2011, public protests arose around income inequality and rising housing and
commodity prices. The government formed committees to address some of the
grievances but has maintained that it will not engage in deficit spending to
satisfy populist demands. In May 2013 the Israeli government, in a politically
difficult process, passed an austerity budget to reign in the deficit and
restore confidence in the government’s fiscal position
|
Source
: CIA |
YES PHARMA LTD.
Telephone 972 2 992 99 33
Fax 972 2 992 99 55
Email: info@yespharma.com
11 Hamelacha Street
Har Tuv A Industrial Park
Nocham Enterprises Har-Tuv 9980101 Israel
A private limited company, incorporated as per file No. 51-363979-9 on the 17.01.2005.
Authorized share capital NIS 10,000.00, divided into -
1,000,000 ordinary shares of NIS 0.01 each,
of which 10,000 shares amounting to NIS 100.00 were issued.
Subject is fully owned by Gideon Schurder.
Gideon Schurder, born in 1976.
Agencies in the field of raw materials for the pharmaceutical branch (pharma Intermediates, Active Pharmaceuticals Ingredient's (APIs), formulations to biopharmaceuticals).
Also international traders in raw materials for the pharmaceutical field.
Local sales are via sister company YES PHARMA ISRAEL 2008 LTD.
All sales are on a commission basis.
95% of sales are export.
All of subject’s suppliers are foreign.
Among customers: TEVA PHARMACEUTICAL INDUSTRIES, DEXCEL, TARO PHARMACEUTICAL INDUSTRIES, PERRIGO ISRAEL, CTS CHEMICAL INDUSTRIES, RAFA LABORATORIES, etc.
Sole local agents of:
CIPLA, NICHOLAS PIRAML, INDSWIFT, RANDEXY, BENZOCHEM, all of India,
STEROID, of Italy,
INTERQUIM, CRYSTAL PHARMA, both of Spain,
ACG, of India (in the capsule field).
Operating from rented premises, on an area of 520 sq. meters, in 11 Hamelacha Street, Sofri House, Har Tuv A Industrial Park, Nocham Enterprises Har-Tuv, Mateh Yehuda Regional Council, situated near Beit Shemesh.
Having 16 employees serving subject and sister company (same as in 2013, had 14 employees in mid 2012, same as in 2011 and 2010).
Holding no stocks, work is based on orders.
Financial data not forthcoming.
There are 3 charges for unlimited amounts, as well as 1 charge for the sum of US$ 75,000.00 registered on the company assets (financial assets), in favor of Bank Hapoalim Ltd. (last charge placed April 2012).
Actual revenues derive from commission on sales. Consolidated revenues are by subject and sister company:
2007 consolidated sales claimed to be US$ 4,700,000, of which 80% were sales abroad.
2008 consolidated sales claimed to be US$ 9,800,000, of which 80% were sales abroad.
2009 consolidated sales claimed to be US$ 6,000,000, of which 80% were sales abroad.
2010 consolidated sales claimed to be US$ 9,200,000, of which 90% were sales abroad.
2011 consolidated sales claimed to be US$ 13,000,000, of which 90% were sales abroad.
2012 consolidated sales claimed to be US$ 18,000,000, of which 90% were sales abroad.
2013 consolidated sales were US$ 22,000,000, of which US$ 21,694,000 were by subject. 95% of sales were abroad (export).
YES PHARMA ISRAEL 2008 LTD., fully owned by Gideon Schurder, agencies in Israel for pharmaceutical raw materials, operating on a very low volume.
Bank Hapoalim Ltd., Jerusalem Business Branch (No.436), Jerusalem, account
No. 222000.
Bank Leumi Le'Israel Ltd., Har Hotzvim Business Branch (No. 968), Jerusalem, account No. 566200/73.
A check with the Central Banks' database did not reveal anything detrimental on subject’s a/m accounts.
Nothing unfavorable learned.
Subject is ISO 9001:2008 certified.
In February 2010
subject announced on the implementation of ERP/CRM System (Priority, carried
out by ESHBEL TECHNOLOGIES) into their infrastructure.
Over 90% of sales by the local Pharmaceutical Industry are for export.
Sales for exports of pharmaceuticals in 2013 reached US$ 6,348 million, representing 7.3% decrease from 2012 (fall was sharper in local NIS currency terms, by 13.4%), continuing the downward trend from 2012 when it fell some 6% from 2011 (after 10% and 41.5% increase in 2011 and 2010, respectively, from the previous years).
Good for trade engagements.
Note: We are informed that P.O. Box 11075 which you gave is irrelevant.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.60.10 |
|
|
1 |
Rs.99.85 |
|
Euro |
1 |
Rs.82.58 |
INFORMATION DETAILS
|
Report Prepared
by : |
NIS |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall
operation is considered normal. Capable to meet normal commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SC’s
credit risk and to set the amount of credit to be extended. It is calculated
from a composite of weighted scores obtained from each of the major sections of
this report. The assessed factors and their relative weights (as indicated
through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.